Grail, Inc. (NASDAQ:GRAL - Get Free Report) was up 9.8% during trading on Monday . The company traded as high as $43.88 and last traded at $44.71. Approximately 836,409 shares traded hands during mid-day trading, a decline of 43% from the average daily volume of 1,480,114 shares. The stock had previously closed at $40.73.
Analyst Ratings Changes
A number of equities analysts recently weighed in on the stock. Wolfe Research started coverage on shares of Grail in a research report on Friday, November 15th. They set a "peer perform" rating on the stock. Morgan Stanley initiated coverage on Grail in a report on Wednesday, November 27th. They set an "equal weight" rating and a $16.00 target price on the stock.
Read Our Latest Research Report on GRAL
Grail Stock Down 11.3 %
The business has a 50 day simple moving average of $27.15 and a 200-day simple moving average of $19.44.
Grail (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($1.86) EPS for the quarter, topping analysts' consensus estimates of ($4.41) by $2.55. The firm had revenue of $38.25 million for the quarter, compared to analysts' expectations of $35.33 million. Sell-side analysts anticipate that Grail, Inc. will post -15.15 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in GRAL. Crcm LP acquired a new stake in Grail during the fourth quarter worth $65,061,000. Sessa Capital IM L.P. acquired a new stake in shares of Grail during the 4th quarter worth about $53,550,000. Primecap Management Co. CA purchased a new stake in Grail in the 4th quarter valued at about $37,118,000. Baker BROS. Advisors LP acquired a new position in Grail in the fourth quarter valued at about $29,098,000. Finally, Vanguard Group Inc. purchased a new position in Grail during the fourth quarter worth about $25,902,000.
About Grail
(
Get Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Recommended Stories
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
